Literature DB >> 34596727

Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin.

Xiaotong Xia1, Jinglan Fu1, Tingting Wu1, Wenjun Chen1, Shaojun Jiang1, Meina Lv1, Jinhua Zhang2.   

Abstract

PURPOSE: The purpose of this study was to analyse the effects of demographic factors, clinical factors, and genetic polymorphisms of related gene loci on warfarin bleeding-related complications in the Han population.
METHODS: Retrospective medical record review. The study cases were patients treated at the Fujian Medical University Union Hospital from March 2016 to February 2020, and all received regular warfarin anticoagulation treatment for at least 3 months, and were provided the initial standard dose and stable dose of warfarin.
RESULTS: Data were collected from 451 qualifying patients (47% male, 53% female). The average age of patients was 53.8 ± 12.2 years, and the average body surface area was 1.6 ± 0.18 m2. There were nine major bleeding events and 141 minor bleeding events. In the univariate logistic analysis, the p-value of the four factors body weight, body surface area (BSA), amiodarone, and rs429358 was < 0.10. However, the final p-values for amiodarone and rs429358 were < 0.05 in the multifactorial logistic analysis.
CONCLUSIONS: The ApoE (rs429358) gene polymorphism influences bleeding complications in Chinese Han patients treated with warfarin. The sample size of this study was relatively small; hence an international study with a larger sample size is needed in the future.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Bleeding complications; Demographic characteristics; Gene polymorphism; Han population; Warfarin

Mesh:

Substances:

Year:  2021        PMID: 34596727     DOI: 10.1007/s00228-021-03204-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  29 in total

1.  Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.

Authors:  Shi-Long Zhong; Xi-Yong Yu; Yuan Liu; Dan Xu; Li-Ping Mai; Hong-Hong Tan; Qiu-Xiong Lin; Min Yang; Shu-Guang Lin
Journal:  Pharmacogenet Genomics       Date:  2012-03       Impact factor: 2.089

2.  Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.

Authors:  Espen Molden; Cecilie Okkenhaug; Erik Ekker Solberg
Journal:  Eur J Clin Pharmacol       Date:  2010-03-31       Impact factor: 2.953

3.  Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease.

Authors:  K K Wu; N Aleksic; C Ahn; E Boerwinkle; A R Folsom; H Juneja
Journal:  Circulation       Date:  2001-03-13       Impact factor: 29.690

4.  Thrombomodulin gene mutations associated with myocardial infarction.

Authors:  H Ireland; G Kunz; K Kyriakoulis; P J Stubbs; D A Lane
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

5.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

6.  Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians.

Authors:  H Schelleman; Z Chen; C Kealey; A S Whitehead; J Christie; M Price; C M Brensinger; C W Newcomb; C F Thorn; F F Samaha; S E Kimmel
Journal:  Clin Pharmacol Ther       Date:  2007-02-28       Impact factor: 6.875

7.  Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

Authors:  J Taube; D Halsall; T Baglin
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

8.  An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

Authors:  Lisa M Meckley; Ann K Wittkowsky; Mark J Rieder; Allan E Rettie; David L Veenstra
Journal:  Thromb Haemost       Date:  2008-08       Impact factor: 5.249

9.  Aniticoagulation in patients following prosthetic heart valve replacement.

Authors:  Raja Parvez Akhtar; Abdul Rehman Abid; Hasnain Zafar; Jawad Sajid Khan
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-02       Impact factor: 1.520

10.  Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.

Authors:  N A Limdi; G McGwin; J A Goldstein; T M Beasley; D K Arnett; B K Adler; M F Baird; R T Acton
Journal:  Clin Pharmacol Ther       Date:  2007-07-25       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.